GW PHARMACEUTICALS PLC AMERICA (GWPH) Covered Calls

GW PHARMACEUTICALS PLC AMERICA covered calls GW Pharmaceuticals PLC is engaged in the research, development and commercialisation of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions.

You can sell covered calls on GW PHARMACEUTICALS PLC AMERICA to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GWPH (prices last updated Fri 4:16 PM ET):

GW PHARMACEUTICALS PLC AMERICA (GWPH) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
136.06 +2.13 131.00 136.50 251K - 3.9B
Covered Calls For GW PHARMACEUTICALS PLC AMERICA (GWPH)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Sep 21 135 5.50 131.00 3.1% 31.4%
Nov 16 135 9.90 126.60 6.6% 26.2%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

GW Pharmaceuticals Plc engages in the business of discovering, developing and commercializing novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development and Pipeline Research & Development. The Commercial segment promotes Sativex through strategic collaborations with major pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the Group's proprietary cannabinoid technology platform. GW Pharmaceuticals was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Salisbury, the United Kingdom.